Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 183

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity

Open access
Bonday, Zahid Q., Cortez, Guillermo S., Grogan, Michael J., Antonysamy, Stephen, Weichert, Ken, Bocchinfuso, Wayne P., Li, Fengling, Kennedy, Steven, Li, Binghui, Mader, Mary M., Arrowsmith, Cheryl H., Brown, Peter J., Eram, Mohammad S., Szewczyk, Magdalena M., Barsyte-Lovejoy, Dalia, Vedadi, Masoud, Guccione, Ernesto, Campbell, Robert M.·2018·ACS Medicinal Chemistry Letters

Abstract

Protein arginine methyltransferase 5 (PRMT5) is a type II arginine methyltransferase that catalyzes the formation of symmetric dimethylarginine in a number of nuclear and cytoplasmic proteins. Although the cellular functions of PRMT5 have not been fully unraveled, it has been implicated in a number of cellular processes like RNA processing, signal transduction, and transcriptional regulation. PRMT5 is ubiquitously expressed in most tissues and its expression has been shown to be elevated in several cancers including breast cancer, gastric cancer, glioblastoma, and lymphoma. Here, we describe the identification and characterization of a novel and selective PRMT5 inhibitor with potent in vitro and in vivo activity. Compound 1 (also called LLY-283) inhibited PRMT5 enzymatic activity in vitro and in cells with IC 50 of 22 ± 3 and 25 ± 1 nM, respectively, while its diastereomer, compound 2 (also called LLY-284), was much less active. Compound 1 also showed antitumor activity in mouse xenografts when dosed orally and can serve as an excellent probe molecule for understanding the biological function of PRMT5 in normal and cancer cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acsmedchemlett.8b00014

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 183

Metadata

Authors
Bonday, Z. Q., Cortez, G. S., Grogan, M. J., Antonysamy, S., Weichert, K., Bocchinfuso, W. P., Li, F., Kennedy, S., Li, B., Mader, M. M., Arrowsmith, C. H., Brown, P. J., Eram, M. S., Szewczyk, M. M., Barsyte-Lovejoy, D., Vedadi, M., Guccione, E., & Campbell, R. M.
Venue
ACS Medicinal Chemistry Letters
Published
2018-04-23
Volume
9
Issue
7
Pages
612-617
ISSN
1948-5875 (ISSN-L)
OpenAlex
W2800877169
Cited by
183
References
1
FWCI
6.12
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity. https://app.cochat.ai/papers/10.1021/acsmedchemlett.8b00014
The paper
Bonday, Z. Q., Cortez, G. S., Grogan, M. J., Antonysamy, S., Weichert, K., Bocchinfuso, W. P., Li, F., Kennedy, S., Li, B., Mader, M. M., Arrowsmith, C. H., Brown, P. J., Eram, M. S., Szewczyk, M. M., Barsyte-Lovejoy, D., Vedadi, M., Guccione, E., & Campbell, R. M. (2018). LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity. ACS Medicinal Chemistry Letters. https://doi.org/10.1021/acsmedchemlett.8b00014

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.